Literature DB >> 1973382

Clinical use of beta-adrenoceptor blockade in systemic hypertension.

J Nadelmann1, W H Frishman.   

Abstract

beta-Blockers are effective in reducing the blood pressure of many patients with systemic hypertension. They differ in terms of the presence or absence of intrinsic sympathomimetic activity, membrane-stabilising activity, beta 1-selectivity, alpha-blocking properties, and relative potency and duration of action. All beta-blockers appear to have blood pressure lowering effects. The choice of which beta-blocker to use in an individual patient is determined by the pharmacodynamic and pharmacokinetic differences between the drugs in conjunction with the patient's other medical condition(s). This review discusses the practical use of beta-blockers and provides rational suggestions for which drug(s) to use in selected patient groups (Black, elderly, postinfarction, diabetes, renal disease, obstructive lung disease, elevated lipid levels, coexisting angina, and left ventricular hypertrophy).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973382     DOI: 10.2165/00003495-199039060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  74 in total

Review 1.  Drug therapy: metoprolol.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

Review 2.  Intrinsic sympathomimetic activity of beta-adrenoceptor blocking agents.

Authors:  G Cocco; F Burkart; D Chu; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

3.  Comparison of atenolol and propranolol during insulin-induced hypoglycaemia.

Authors:  S P Deacon; D Barnett
Journal:  Br Med J       Date:  1976-07-31

4.  Propranolol-induced hypoglycaemia and myocardial infarction.

Authors:  R Wray; S B Sutcliffe
Journal:  Br Med J       Date:  1972-06-03

Review 5.  The beta-adrenoceptor blocking drugs.

Authors:  W H Frishman
Journal:  Int J Cardiol       Date:  1982       Impact factor: 4.164

Review 6.  Nadolol: a new beta-adrenoceptor antagonist.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1981-09-17       Impact factor: 91.245

7.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

Review 8.  Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

9.  Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol.

Authors:  L Corea; M Bentivoglio; P Verdecchia; M Provvidenza; M Motolese
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-07

10.  Cardiac hypertrophy and antihypertensive therapy.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Cardiovasc Res       Date:  1977-09       Impact factor: 10.787

View more
  6 in total

Review 1.  A practical guide to the management of hypertension in renal transplant recipients.

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

4.  The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

Authors:  Jean Lefebvre; Luc Poirier; Paul Poirier; Jacques Turgeon; Yves Lacourciere
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

Review 5.  Selenium-based antihypertensives. Rationale and potential.

Authors:  S W May; S H Pollock
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 6.  Which ancillary properties of beta-adrenoceptor blocking drugs influence their therapeutic or adverse effects?: a review.

Authors:  P Turner
Journal:  J R Soc Med       Date:  1991-11       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.